Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant...
Patent
1985-05-16
1989-07-25
Terapane, John F.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
534 14, 424 9, A61K 4902, A61K 4900
Patent
active
048512095
ABSTRACT:
A novel diagnostic procedure for the in vivo clinical evaluation of gastrointestinal ulcer disease and other diseases associated with loss of mucosal integrity in humans which comprises the oral administration of an effective amount of radio-labeled sucralfate or derivative or precusor thereof or a water soluble, physiologically compatible radiolabeled salt of sucrose suflate to the human host, followed by scintigraphic imaging of the gastrointestinal area of interest with scintigraphic imaging equipment.
A novel radiopharmaceutical composition comprising an aqueous solution or suspension containing an amount of a radio-labeled sucralfate or derivative or precursor thereof or a water soluble, physiologically compatible radiolabeled salt of sucrose sulfate for in vivo scintigraphic imaging of the gastrointestinal or other muscosal areas in humans.
REFERENCES:
patent: 3432489 (1969-03-01), Nitta et al.
patent: 3852413 (1974-12-01), Cammarata
patent: 4243652 (1981-01-01), Francis
patent: 4385046 (1983-05-01), Milbrath et al.
patent: 4581221 (1986-04-01), Kuperus
Nagashima et al., Arzneimittel Forschung, 30(1), 80-91, (1980).
Wu et al., Nuclear Medicine and Biology Advances, 3, 2961-2963.
Braunstein et al., Abstract from American Gastroenterological Assn., May 23, 1983, "Detection of Peptic Ulcer Disease by Nuclear Scintigraphy Using an Ulcer Avid Acent".
P. Braunstein, 1983 Abstract, Soc. of Nuclear Medicine, Jun. 7-8, 1983, "Tagged Ulcer-Avid Material Imaging (Tumi): A Potent New Method for the Evaluation of Peptic Ulcer Disease".
Journal of Clinical Gastroenterology, Supp. 2, 1981, "Sucralfate Mechanisms of Action".
Arzneim Forsch/Drug Res. 30(I), Nr.1, 1980, N. Hirano, "Sucralfate".
Arzneim-Forsch/Drug Res. 30 (I), 1979, Several Articles, pp. 73-80.
Vasquez, T., Radiology 148: 227-231, Jul. 1983, "Work in Progress, Gastro-Intestinal Ulcerations: Detection Using a Technetium-99 m-Labeled Ulcer-Avid Agent".
Vasquez, T., Jour. Nuc. Med., 30: No. 2-3, 1986, "Radionuclide Imaging Using Technetium-99 m Labeled Sucralfate and Potassium Sucrose Sulfate to Detect Gastric and Duodenal Ulcers".
Vasquez, T., From FDA IND Application, 7-27-84, "Detection of Upper Gastro-Intestinal Tract Mucosal Injury with a Radiolabeled Ulcer-Avid Agent".
Vasquez, Tony, Abstract, 9/3/82, "Nuclear Imaging of Gastrointestinal (G.I.) Ulceration: A New Non Invasive Procedure Using an Ulcer Avid Agent".
Vasquez, T., 8-Radiation, vol. 99:49703q, p. 49704, "Work in progress. Gastrointestinal Ulcerations: Detecting Using a Technetium-99-m-Labeled Ulcer-Avid agent".
Wu, R. K., Nuc. Med. and Bio. Advances, Radiation, Aug., 1982, "Radiation Dose Calculations for Orally Administered Radio-Pharmaceuticals in Upper Gastrointestinal Disease".
Braunstein Philip
Bridges Robert L.
Jansholt Anne-Line
Vasquez Tony E.
Terapane John F.
The Regents of the University of California
Thomas J. E.
LandOfFree
Diagnostic procedures using radio labeled sucralfate and derivat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic procedures using radio labeled sucralfate and derivat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic procedures using radio labeled sucralfate and derivat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2356936